

## Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	<b>C. freundii</b>		<b>C. koseri</b>		<b>E. aerogenes</b>		<b>E. cloacae</b>		<b>E. coli</b>		<b>K. oxytoca</b>	
Amikacin	392	100%	140	100%	293	100%	777	100%	12622	100%	651	100%
Ampicillin	-	-	-	-	-	-	-	-	12622	68%	-	-
Ampicillin/Sul	-	-	140	92%	-	-	-	-	12622	70%	651	55%
Aztreonam	391	86%	140	98%	293	88%	776	87%	12622	96%	651	97%
Cefazolin	-	-	140	92%	-	-	-	-	12622	84%	651	39%
Cefepime	392	97%	140	99%	293	99%	777	94%	12622	96%	651	97%
Cefoxitin	-	-	130	95%	-	-	-	-	11976	96%	631	97%
Ceftazidime	392	85%	140	99%	293	88%	777	87%	12622	96%	651	97%
Ceftriaxone	392	82%	140	98%	293	85%	777	84%	12622	96%	651	96%
Ciprofloxacin	13	85%	10	100%	13	100%	31	100%	645	92%	20	100%
Ertapenem	392	97%	140	100%	-	-	777	91%	12622	100%	651	100%
Gentamicin	392	95%	140	100%	293	100%	777	98%	12622	95%	651	99%
Imipenem	392	94%	140	99%	-	-	777	93%	12622	100%	651	99%
Levofloxacin	392	96%	140	100%	293	99%	777	99%	12622	89%	651	99%
Meropenem	379	99%	130	100%	280	100%	746	99%	11977	100%	631	100%
*Nitrofurantoin	350	93%	116	34%	248	23%	576	48%	11835	98%	481	91%
Piperac/Tazo	392	87%	140	98%	293	87%	777	88%	12622	99%	651	95%
Tetracycline	392	84%	140	99%	293	96%	777	90%	12622	83%	651	94%
Tobramycin	392	94%	140	99%	293	100%	777	98%	12622	95%	651	98%
Trim/Sulfa	392	86%	140	99%	293	98%	777	93%	12622	84%	651	94%

\* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Low number of isolates. Results are less statistically valid.

**Reprints and additional information available at:**

<http://home.nordx.mmc.org/depts/micro/docs/indx.htm>

### Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	<b>K. pneumoniae</b>		<b>M. morgani</b>		<b>P. mirabilis</b>		<b>P.aeruginosa</b>		<b>S.marcescens</b>		<b>Ac. baumannii</b>	
Amikacin	2335	100%	202	100%	1053	100%	1030	100%	309	100%	42	95%
Ampicillin	-	-	-	-	1053	84%	-	-	-	-	-	-
Ampicillin/Sul	2335	84%	202	19%	1053	89%	-	-	-	-	42	95%
Aztreonam	2335	96%	202	95%	1053	99%	1030	83%	309	100%	-	-
Cefazolin	2335	88%	202	0%	1053	2%	-	-	-	-	-	-
Cefepime	2335	96%	202	100%	1053	99%	1030	94%	309	99%	42	95%
Cefoxitin	2237	93%	201	74%	1015	98%	-	-	-	-	-	-
Ceftazidime	2335	96%	202	90%	1053	100%	1030	94%	309	100%	-	-
Ceftriaxone	2335	96%	202	93%	1053	98%	-	-	309	95%	37	76%
Ciprofloxacin	98	94%	-	-	37	81%	20	95%	9	100%	-	-
Ertapenem	2335	99%	202	98%	1053	99%	-	-	309	97%	-	-
Gentamicin	2335	97%	202	93%	1053	92%	1030	95%	309	99%	42	93%
Imipenem	2335	98%	-	-	-	-	1030	79%	309	62%	42	95%
Levofloxacin	2335	98%	202	90%	1053	82%	1030	85%	309	99%	42	98%
Meropenem	2237	100%	201	98%	-	-	1010	93%	300	99%	41	95%
*Nitrofurantoir	2053	42%	-	-	-	-	-	-	-	-	-	-
Piperac/Tazo	2335	96%	202	98%	1053	99%	1030	91%	309	97%	-	-
Tetracycline	2335	85%	-	-	-	-	-	-	309	0%	11	100%
Tobramycin	2335	96%	202	95%	1053	92%	1030	98%	309	79%	42	98%
Trim/Sulfa	2335	90%	202	83%	1053	84%	-	-	-	-	42	93%

\* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

ESBL incidence rate for 2019 was 3.4%

CRE incidence rate for 2019 was 0.57%

CP-CRE incidence rate for 2019 was 0.04%

**Reprints and additional information available at:**

<http://home.nordx.mmc.org/depts/micro/docs/Index.htm>

## Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	<b>E. faecalis</b>		<b>E. faecium</b>		<b>S. aureus</b>		<b>S. epidermidis</b>		<b>***MSSA***</b>		<b>***MRSA***</b>	
Ampicillin	1922	100%	201	36%	-	-	-	-	-	-	-	-
Cefazolin	-	-	-	-	4364	73%	1352	55%	3419	99%	1212	1%
Clindamycin	-	-	-	-	4087	80%	620	64%	3191	81%	1150	76%
Daptomycin	1922	99%	201	99%	4365	100%	1352	100%	3419	100%	1213	100%
Doxycycline	1922	35%	201	68%	4364	97%	1351	88%	3418	98%	1213	95%
Erythromycin	462	18%	65	11%	4023	54%	544	45%	3148	69%	1121	14%
Gentamicin	-	-	-	-	4365	99%	1239	100%	3419	99%	1213	96%
Levofloxacin	1463	86%	136	26%	4365	83%	1352	71%	3419	93%	1213	53%
Linezolid	1922	99%	201	91%	4365	100%	1352	100%	3419	100%	1213	100%
Moxifloxacin	-	-	-	-	4023	84%	477	100%	3148	94%	1121	56%
*Nitrofurantoin	1465	100%	-	-	352	100%	811	100%	279	100%	94	100%
Oxacillin	-	-	-	-	4365	73%	1352	55%	3419	99%	1213	0%
Penicillin	-	-	-	-	-	-	-	-	-	-	-	-
Quinupr/Dalfo	-	-	201	76%	4365	100%	-	-	3419	100%	1213	100%
#Rifampin	-	-	-	-	4365	99%	1352	99%	3419	99%	1213	99%
Tetracycline	1465	23%	136	33%	4365	92%	1352	82%	3419	92%	1213	93%
Trim/Sulfa	-	-	-	-	4365	96%	-	-	3419	97%	1213	94%
Vancomycin	1922	99%	201	53%	4365	100%	1352	100%	3419	100%	1213	100%
Gent Synergy	1922	86%	201	94%	-	-	-	-	-	-	-	-
Strep Synergy	1922	87%	201	87%	-	-	-	-	-	-	-	-

	<b>H. influenzae</b>		<b>S. pneumoniae</b>			
			Susceptible		Intermediate	
Ampicillin	13	69%	-	-	-	-
Amox/Clav	3	100%	-	-	-	-
Ceftriaxone	13	100%	248	100%	0%	0%
Ceftriaxone(Meningitis)	-	-	171	97%	3%	0%
Levofloxacin	-	-	215	97%	-	-
Meropenem	11	100%	105	89%	2%	0%
Penicillin	-	-	231	81%	17%	0%
#Rifampin	-	-	36	100%	-	-
Tetracycline	-	-	214	83%	-	-
Trim/Sulfa	2	100%	-	-	-	-
Vancomycin	-	-	106	100%	-	-

\* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

# Rifampin should not be used alone for therapy.

Low number of isolates. Results are less statistically valid

Routine testing of Haemophilus was discontinued in 2016.

HI is tested from sterile sites or upon request.